COVID-19 and metabolic disease: mechanisms and clinical management. Issue 11 (November 2021)

• Record Type: Journal Article
• Authors: Steenblock, Charlotte; Schwarz, Peter E H; Ludwig, Barbara; Linkermann, Andreas; Zimmet, Paul; Kulebyakin, Konstantin; Tkachuk, Vsevolod A; Markov, Alexander G; Lehnert, Hendrik; de Angelis, Martin Hrabě; Rietzsch, Hannes; Rodionov, Roman N; Khunti, Kamlesh; Hopkins, David; Birkenfeld, Andreas L; Boehm, Bernhard; Holt, Richard I G; Skyler, Jay S; DeVries, J Hans; Renard, Eric; Eckel, Robert H; Alberti, K George M M; Geloneze, Bruno; Chan, Juliana C; Mbanya, Jean Claude; Onyegbutulem, Henry C; Ramachandran, Ambady; Basit, Abdul; Hassanein, Mohamed; Bewick, Gavin; Spinas, Giatgen A; Beuschlein, Felix; Landgraf, Rüdiger; Rubino, Francesco; Mingrone, Geltrude; Bornstein, Stefan R;
• Is Part Of: Lancet. Volume 9:Issue 11(2021)
• Page Start: 786
• Page End: 798
• Publication Date: 2021-11
• Subjects: Diabetes -- Periodicals; Endocrinology -- Periodicals; Endocrine glands -- Diseases -- Periodicals; 616.4
• DOI: 10.1016/S2213-8587(21)00244-8
• Languages: English
• ISSNs: 2213-8587

Abstract

Summary: Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.